Insider Transactions in Q2 2024 at Kala Pharmaceuticals, Inc. (KALA)
Insider Transaction List (Q2 2024)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 26
2024
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
5,489
-6.13%
|
$21,956
$4.75 P/Share
|
Jun 26
2024
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
15,168
-5.44%
|
$60,672
$4.75 P/Share
|
Jun 26
2024
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,163
-6.47%
|
$16,652
$4.75 P/Share
|
Jun 26
2024
|
Darius Kharabi CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
5,158
-7.95%
|
$20,632
$4.75 P/Share
|
Jun 26
2024
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
4,653
-5.31%
|
$18,612
$4.75 P/Share
|
Jun 11
2024
|
Mark S. Blumenkranz |
BUY
Grant, award, or other acquisition
|
Direct |
1,400
+9.66%
|
-
|
Jun 11
2024
|
Andrew I Koven |
BUY
Grant, award, or other acquisition
|
Direct |
1,750
+11.17%
|
-
|
Jun 11
2024
|
C. Daniel Myers |
BUY
Grant, award, or other acquisition
|
Direct |
1,400
+15.02%
|
-
|
Jun 11
2024
|
Gregory D Perry |
BUY
Grant, award, or other acquisition
|
Direct |
1,400
+11.39%
|
-
|
Jun 11
2024
|
Marjan Farid |
BUY
Grant, award, or other acquisition
|
Direct |
1,400
+15.23%
|
-
|
Jun 11
2024
|
Howard B Rosen |
BUY
Grant, award, or other acquisition
|
Direct |
1,400
+9.16%
|
-
|
May 31
2024
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,392
-2.58%
|
$44,352
$6.09 P/Share
|
May 31
2024
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
2,002
-2.19%
|
$12,012
$6.09 P/Share
|
May 31
2024
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,786
-2.7%
|
$10,716
$6.09 P/Share
|
May 31
2024
|
Darius Kharabi CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
231
-0.35%
|
$1,386
$6.09 P/Share
|
May 31
2024
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
2,093
-2.33%
|
$12,558
$6.09 P/Share
|